Acute myeloid leukemia (AML) is a genetically heterogeneous disease that, even with current advancements in therapy, continues to have a poor prognosis. Recurrent somatic mutations have been identified in a core set of pathogenic genes including FLT3 (25-30% prevalence), NPM1 (25-30%), DNMT3A (25-30%), IDH1/2 (5-15%), and TET2 (5-15%), with direct diagnostic, prognostic, and targeted therapeutic implications. Advances in the understanding of the complex mechanisms of AML leukemogenesis have led to the development and recent US Food and Drug Administration (FDA) approval of several targeted therapies: midostaurin and gilteritinib targeting activated FLT3, and ivosidenib and enasidenib targeting mutated IDH1/2. Several additional drug candidates targeting other recurrently mutated gene pathways in AML are also being actively developed. Furthermore, outside of the realm of predicting responses to targeted therapies, many other mutated genes, which comprise the so-called long tail of oncogenic drivers in AML, have been shown to provide clinically useful diagnostic and prognostic information for AML patients. Many of these recurrently mutated genes have also been shown to be excellent biomarkers for post-treatment minimal residual disease (MRD) monitoring for assessing treatment response and predicting future relapse. In addition, the identification of germline mutations in a set of genes predisposing to myeloid malignancies may directly inform treatment decisions (particularly stem cell transplantation) and impact other family members. Recent advances in sequencing technology have made it practically and economically feasible to evaluate many genes simultaneously using next-generation sequencing (NGS). Mutation screening with NGS panels has been recommended by national and international professional guidelines as the standard of care for AML patients. NGS-based detection of the heterogeneous genes commonly mutated in AML has practical clinical utility for disease diagnosis, prognosis, prediction of targeted therapy response, and MRD monitoring. Fei Yang and Tauangtham Anekpuritanang contributed equally to this article.
Introduction
Acute myeloid leukemia (AML) results from the clonal expansion of mutation-altered hematopoietic stem cells (HSCs) and hematopoietic progenitor cells in which these acquired genomic aberrations provide a selective growth advantage and impede normal hematopoiesis. It is one of the most aggressive cancers, with a 5-year overall survival for adult patients being disappointedly low at 24-28% [1, 2] . The initial treatment of AML continues to rely on the use of non-specific (highly toxic) chemotherapeutic drugs to reduce the burden of rapidly proliferating leukemic cellsusually a combination of cytarabine and an anthracycline. Following this initial induction chemotherapy regimen (with or without concomitant targeted therapy in eligible patients), the longer-term clinical management of AML is significantly based on prognostic risk stratification of the initial leukemia-the goal being to direct more intense (more toxic) therapy only to those patients predicted to be at the highest risk of disease progression, and spare lower-risk patients, deemed less likely to benefit, from the consequent toxicity. In addition to patient age and the morphologic/immunophenotypic assessment of leukemic blasts, specific cytogenetic and molecular genetic abnormalities are the critical and consensus prognostic biomarkers for AML [3, 4] . Prior to the next-generation sequencing (NGS) era, for example, activating mutations in FLT3 were proven to predict a poor prognosis (suggesting possible benefit from higher-intensity therapy), while mutations in CEBPA (bi-allelic) or NPM1 were predictive of a relatively favorable prognosis. More recent large cohort studies [5] [6] [7] [8] have identified a heterogeneous diversity of leukemogenic AML-associated oncogenic driver mutations in genes from several diverse functional categories, including NPM1, signal transduction proteins (FLT3, NRAS, PTPN11, WT1, KRAS, KIT, CBL, NF1, CBLB, etc.), transcription factors (CEBPA, RUNX1, GATA2, ETV6, CUX1, etc.), epigenetic regulators (DNMT3A, TET2, IDH1, IDH2, ASXL1, EZH2, EP300, BCOR), spliceosomecomplex genes (SF3B1, SRSF2, U2AF1, ZRSR2), tumor suppressor genes (TP53, PHF6, PPM1D), and cohesin complex genes (STAG2, RAD21, SMC1, SMC2). Most AML cases are driven by a complex multi-gene sequence of acquired mutations in genes from more than three distinct biological pathways. Predictably, as many of these same somatic driver mutations have been shown to carry practical prognostic significance [5-7, 9, 10] of clinical benefit for predicting posttreatment disease recurrence, molecular diagnostic methods for their detection have transitioned from the research arena to the routine diagnostic clinical laboratory. Historically, these clinically relevant gene mutations have been assessed in the clinical molecular pathology laboratory by established 'single-gene' methods such as Sanger sequencing, real-time polymerase chain reaction (PCR) (RT-PCR), PCR-fragment analysis, high-resolution melting, etc. With the recent availability of robust methods for massively parallel NGS, however, many laboratories have transitioned AML mutation profiling to this newer technology. The specific advantages of NGS-based methods as compared to multiple 'single-gene' methods include its more efficient use of cells/ tissue, more comprehensive (sensitive) assessment of clinically relevant mutations, enhanced analytical sensitivity (as compared to most, but not all, other molecular methods), uniform technical workflow, and, depending on the number of genes interrogated, lower per-gene testing costs. The comparative disadvantages of NGS, however, include its technical complexity (necessitating long and expensive test development timelines), relatively long turnaround time (often complicating urgent targeted therapeutic decision-making), the need for specialized bioinformatics expertise, the need for specialized variant annotation/curation/database expertise, the considerable up-front instrument costs, the discovery of many 'unintended' variants of unknown significance whose possible clinical relevance may need to be vetted or inferred (often without much published information), and the uncertainty (at least in the USA) of health insurance coverage/reimbursement.
Next-Generation Sequencing (NGS) in Acute Myeloid Leukemia (AML) Diagnosis
The diagnosis of AML continues to be based on the morphologic, immunohistochemical, and/or flow cytometric identification of the myeloid blast cell and/or its equivalent [4] . The goal of AML subclassification has always been to define specific diagnostic entities, each with a unique causality, prognostic, and/or therapeutic implication [7] . Conventional morphological subclassifications [11] [12] [13] have limitations and are now supplemented by more clinically relevant classification schemes based on combined morphologic, immunophenotypic, cytogenetic, and molecular genetic information. The most widely used diagnostic system is the World Health Organization (WHO) classification system [4] , which recognizes several recurrent genetic abnormalities as specifically defined diagnostic entities. While the majority of these genetically defined AML diagnoses are defined by a specific chromosomal translocation (e.g., AML with t(8;21) (q22;q22.1) RUNX1-RUNX1T1), the presence of pathogenic mutations in any of three genes (namely NPM1, CEBPA, and RUNX1) defines a specific diagnostic entity in the current WHO system (Table 1) . Diagnosis-defining chromosomal alterations are usually detected by either a cytogenetic technique (e.g., karyotyping or fluorescent in situ hybridization [FISH]) or RT-PCR (e.g., BCR-ABL1 or PML-RARA fusion transcripts). However, newer technologies such as NGSbased fusion gene panels are being increasingly utilized in the routine clinical diagnostic laboratory to detect these same (and many other) chromosomal translocation events. The detection of NPM1 and CEBPA mutations has been integrated into the initial diagnostic workup of AML for many years, using a variety of techniques designed to interrogate either a specific mutation hotspot (as with NPM1) or heterogeneous mutations across the entire gene (as with CEBPA).
The detection of any of the heterogeneously distributed pathogenic mutations in the RUNX1 gene is a more recent addition to the diagnostic AML workup within most laboratories. Historically, RUNX1 mutation detection was typically undertaken with 'gene-scanning' and/or or Sanger sequencing methods [14] . Within the last few years, however, [81] The prognosis in myeloid neoplasms with germline DDX41 mutation is generally poor [98] One study suggested that these patients may respond to lenalidomide treatment [98] given the increasing availability of NGS, this new method is quickly becoming the 'gold standard' for detecting the AML mutations that define WHO-defined AML subtypes. Within these genetically defined subgroups in the WHO system, only acute promyelocytic leukemia (APL) with a PML-RARA translocation has an associated specific targeted treatment protocol [15] . Mutations in NPM1, CEBPA, and RUNX1 provide relevant prognostic information, with NPM1 and CEBPA mutations conferring a relatively good, and RUNX1 mutations conferring a relatively poor, prognostic outlook. These mutation-defining diagnostic entities linked to specific prognostic subgroups often influence standard chemotherapeutic treatment decisions, but are not tied to the use of specific targeted therapies. In contrast, most of the US Food and Drug Administration (FDA)-approved and experimental targeted therapeutics for AML are directed against leukemic driver mutations that are not specific to any genetically defined WHO diagnostic entity. An accurate diagnosis of AML (and its subtypes) can thus be made by conventional hematopathology laboratory techniques with the addition of cytogenetic and limited molecular genetic testing. It is the prognostic and therapeutic aspects of AML disease management that typically require a more extensive genetic interrogation of additional leukemia-associated genes. 
NGS for Defining Prognosis in AML
Even though each WHO-defined AML entity has its own inherent prognostic implication, alterations in other genes, beyond these three entity-specific genes, also have significant prognostic relevance. Depending on the number of genes targeted by NGS, AMLs have been shown to contain multiple pathogenic driver mutations per tumor (three to four per case in a recent large European cohort) [7] , and, by wholeexome sequencing, an even larger number of total somatic mutations (a median of 13 per case in a recent American cohort) [8] . Many of these heterogeneous mutations have been shown to influence long-term AML prognosis and are thus of direct clinical relevance. Both the National Comprehensive Cancer Network (NCCN) and the European Leuke-miaNet (ELN) thus recognize that the detection of genetic alterations in a diversity of recurrently mutated genes provides practical AML risk stratification information [3, 16] , including both large-scale chromosomal alterations and small-scale gene mutations (FLT3, ASXL1, TP53, IDH1/2, DNMT3A, KMT2A, KIT, etc.; see Table 1 ) that are not distinct diagnostic entities in the WHO classification system. These prognosis-defining mutations affect heterogeneous cellular pathways and often function to initiate and/or maintain the clonal leukemic cell population [5] . The presence of many of these prognosis-defining mutations, either alone or in combination with other mutations, has been shown to predict a specific AML disease outcome. To add to the complexity, even within AML diagnostic subgroups defined by a specific gene mutation, the clinical course often varies based on the presence or absence of specific co-mutations. For example, the relatively favorable prognosis associated with the presence of an NPM1 mutation is mitigated if there is a co-mutation in the FLT3, IDH1/2, and/or DNMT3A genes [17] [18] [19] . Recent reports have even shown that the quantitative mutant allele burden [20] or exact sequence of an NPM1 insertion may also define a different prognosis [21] , further supporting the use of quantitative sequencing assays rather than size determining PCR assays for detecting an NPM1 mutation.
Another WHO AML diagnostic subgroup, AML with myelodysplastic-related change (AML-MRC), is an AML subset with a worse prognosis. To assign this diagnosis, the patient must have (a) an antecedent history of myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm (MDS/MPN); (b) MDS-related features in the diagnostic bone marrow; or (c) cytogenetic alterations characteristic of MDS in the AML diagnostic bone marrow. Lindsley et al. [22] demonstrated that the presence of a set of mutations commonly detected in MDS (SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2; see Table 1 ) in newly diagnosed AML can be used as indirect evidence of a preceding MDS [22] . Given that the prognosis of patients in this molecularly defined AML subgroup is similar to the prognosis of patients with a traditional diagnosis of AML-MRC, the evaluation of these additional MDS-related genes provides important information for risk stratification in patients with AML.
Detecting diagnostically or prognostically relevant mutations in any of these heterogeneous AML-associated genes can be done by either 'single-gene' assays, one gene at a time, or simultaneously by massively parallel NGS. Although single-gene assays are (individually) inexpensive and fast, when strung together in a serial one-by-one workflow within the laboratory (gene A, then gene B, then gene C, etc.), the cumulative cost and turnaround time quickly exceeds what can be achieved by multi-gene NGS. In our laboratory, for example, when more than around five genes or exons are to be interrogated, we find that NGS becomes a less expensive (and more comprehensive) workflow than performing a multiplicity of single-gene (or Sanger sequencing) assays. On the other extreme end of this question regarding 'how many genes to assess?', larger-scale NGS, as in whole-exome or whole-genome panels, is costly, slow, more difficult to interpret, requires considerable bioinformatics expertise, and lacks high-degree coverage depth (making low-level variant detection difficult [23] ). These more comprehensive NGS assays are thus clinically unjustifiable given the absence of convincing clinical utility data for the overwhelming majority of genes in the exome or genome.
NGS for Predicting Therapeutic Responses in AML
The general approach to the initial therapy for non-APL AML has not changed substantially for many years, with conventional induction chemotherapy still being used in the majority of cases [3, 16] . Multiple landmark studies have demonstrated that the constellation of co-occurring mutations in AML is a significant determinant of a patient's response to induction chemotherapy. AML patients younger than 60 years of age who have a mutant FLT3 (ITD), DNMT3A, NPM1, or KMT2A (MLL) (translocation) have been shown to preferentially benefit from induction therapy with high-dose daunorubicin (90 mg/m 2 ) in clinical trials [24] [25] [26] . Patients with secondary AML evolved from MDS-often implied by an NGS profile containing MDS-associated mutations in epigenetic regulator or spliceosome genes (SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, STAG2, or BCOR)-are more resistant to cytotoxic chemotherapy than patients with a de novo AML that arises without an antecedent hematologic disorder [22] . These secondary AML patients can achieve a higher remission rate and prolonged overall survival with CPX-351 treatment, a liposomal formulation of a fixed combination of daunorubicin and cytarabine (Vyxeos ® ) that was approved by the FDA in 2017 [27] . In addition, AML patients with a mutation in the TET2 or TP53 genes have a favorable initial clinical response to hypomethylating agents, such as azacitidine or decitabine, in combination with conventional chemotherapy [27, 28] .
In the last few years, several novel therapies targeting specific activating mutations were shown to have efficacy in AML subjects, and were approved by the US FDA. Midostaurin was the first multipotent tyrosine kinase inhibitor approved for the treatment, in combination with standard chemotherapy, of adult patients with newly diagnosed FLT3-mutated AML, providing a significant improvement in overall survival for those 20-25% of AML patients with an activating FLT3 mutation, internal tandem duplication (ITD), or tyrosine kinase domain (TKD) mutation [29] . Three additional mutation-targeted drugs have recently been approved for adult patients with relapsed or refractory AML, including the IDH1 inhibitor ivosidenib for patients with an IDH1 mutation (~ 5-10% of AML patients) [30] , the IDH2 inhibitor enasidenib [31] for patients with an IDH2 mutation (~ 10% of AML patients), and the FLT3-selective inhibitor gilteritinib for patients with an activating FLT3 mutation [32] . The proven clinical efficacy of these targeted agents now demands the molecular diagnostic assessment of FLT3 and IDH1/2 mutations in newly diagnosed and relapserefractory AML patients, the results of which will directly dictate the use of these drugs. As targeted midostaurin therapy for FLT3-mutated AML must be initiated within 8 days of diagnosis [29] , and complex NGS-based methods often require a longer turnaround time, using NGS as the sole molecular method for treatment decision-making is often quite challenging.
NGS-based methods (depending on the target design) will also confirm mutations in less common leukemogenic driver genes that have only developing or immature scientific evidence as to therapeutic druggability. Many of these developing gene targets are often the focus of active research investigations in various therapeutic and/or diagnostic clinical trials around the world that may be recruiting patients for enrollment [33] . A direct and major advantage of NGS-based mutation profiling is thus the ability to 'match' a patient with a specific gene mutation with an ongoing clinical trial that may provide substantial clinical benefit to the patient. Public (and proprietary private) databases (such as the US National Institute of Health's ClinicalTrials.gov) are available to provide this crucial clinical trial 'matching' service to applicable mutation-positive patients. For AML patients, several drug candidates targeting recurrently mutated AML genes are being explored in various stages of pre-clinical and clinical development [34] . For example, the NEDD8 inhibitor pevonedistat and the mutant TP53 reactivating compound APR-246 are currently in clinical studies for the treatment of AML patients with TP53 mutations (ClinicalTrials.gov identifiers NCT03268954 and NCT03072043). Other novel therapeutic approaches directly informed by molecular diagnostic assessments are being actively explored in the Beat AML trial, sponsored by the Leukemia & Lymphoma Society (LLS), in which the mutation profile is being used to assign up-front personalized targeted therapies in older patients with AML [35] .
Given the heterogeneity of variants that are produced by multi-gene NGS panels, several molecular diagnostic professional societies have recommended consensus methods for classifying and reporting NGS-defined variants [36, 37] that are in use by most diagnostic clinical molecular pathology laboratories. The accurate classification of uncommon variants as to their pathogenicity (and druggability) is often quite challenging and, as per these consensus guidelines, relies, in part, on whether the variant in question has been previously described (in reference databases such as COS-MIC [Catalogue of Somatic Mutations in Cancer] and gno-mAD [Genome Aggregation Database]) in either patients with the pertinent cancer (more likely to be pathogenic) or in normal population genomic databases (less likely to be pathogenic).
Measurable/Minimal Residual Disease Monitoring
Measurable/minimal residual disease (MRD) in AML refers to the presence of leukemic cells below the threshold of detection by conventional morphology, an established therapeutic response denoted as complete remission (CR) [38] . The post-treatment persistence of submicroscopic leukemia, as defined by various MRD laboratory methods, plays a critical role in the management of AML patients by directly informing the extent of the initial response to treatment, the early presence of relapse after an initial CR, and long-term disease surveillance before and after stem cell transplantation. MRD positivity at various timepoints after treatment thus predicts a worse long-term outcome [16] , which may indicate the need for additional or higher-intensity therapy. A number of laboratory methods are available for MRD analysis, with differing degrees of analytical sensitivity for the detection of low-level leukemia cells, ranging from around 10 in 100 by cytogenetics or 1 in 100 by FISH, to 1 in 10 4 to 10 5 for multicolor flow cytometry (MFC) or single-gene real-time quantitative PCR (RQ-PCR) [39] . Another emerging ultra-sensitive molecular technique that shows promise for MRD monitoring is droplet digital PCR (ddPCR), with an analytical sensitivity comparable to, or perhaps even better than, routine RQ-PCR [40] [41] [42] . International recognition of the clinical relevance of universal monitoring of AML patients for MRD stems, in part, from recent consensus guidelines from ELN that include a new "complete remission without MRD" response criteria category that requires MRD testing by molecular diagnostic or flow cytometric methods [3] . However, there are method-specific limitations to these methods. MFC, for example, is technically demanding, and immunophenotypic shifts and possible clonal evolution during treatment can lead to analytical false-negative results. Clinical false-negative results are also common, with 20-40% of MFC-MRD-'negative' AML patients eventually relapsing [43, 44] . Single-gene RQ-PCR/ddPCR methods for MRD determinations are also subject to false-negative results due to clonal evolution, as AML patients can relapse with different mutations than have been previously reported [45] . For example, a significant minority of patients with NPM1-mutated AML can relapse with a wild-type NPM1 leukemic clone, suggesting that MRD detection using singlegene assays may not be ideal [46] . Furthermore, only ~ 40% of AML patients have a detectable mutation that is technically targetable by a single-gene PCR method. Thus, NGSbased assessment of MRD is becoming increasingly attractive as an MRD tool for its ability to simultaneously assess multiple genes (at a low per-gene cost), thus expanding the applicability of MRD monitoring to a much larger fraction of AML patients-90-97% in most studies [47] [48] [49] [50] . In addition to their broad clinical applicability, NGS-based MRD detection methods are also analytically quite sensitive, with a low-level detection limit in our laboratory of ~ 0.2% (which is better than flow cytometry) at an average read depth of 2500 × [50] . Newer methods for molecular barcoding and bioinformatics background subtraction promise to significantly improve these low-level detection limits for NGSbased MRD to the 0.01% range soon [51, 52] . However, the required read depth to achieve this sensitivity will have to be increased, which will impact the cost and clinical throughput of the NGS test. Reducing sequencing errors using dualindex technology [53] or a smaller NGS panel design targeting core AML-associated genes could be considered to ameliorate this issue.
Multiple studies have demonstrated a strong correlation between NGS-based MRD status and the subsequent risk for relapse in AML patients. The powerful prognostic significance of MRD determinations, independent of other risk factors, has been demonstrated at various post-treatment timepoints, including after initial induction therapy [48, [54] [55] [56] [57] and before [50, 51] and after [58] stem cell transplantation. A persisting positive MRD determination at each of these timepoints is associated with an increased risk of relapse. Furthermore, after completion of therapy, 'molecular relapses' (as defined by ultra-sensitive molecular diagnostic MRD methods) predict subsequent overt hematologic relapses within a 3-to 6-month timeframe [16] . Given this body of evidence, consensus guidelines now recommend post-treatment laboratory evaluations of MRD upon completion of initial induction chemotherapy, before stem cell transplantation, and, depending on the treatment regimen, at other timepoints as well, including post-transplant disease monitoring [16, 38] . The expanding laboratory availability of NGS-based methods for AML mutation profiling, both before and after the initial diagnosis, suggests that much of this MRD monitoring will be performed with NGS. Although there is no definitive prospective evidence that pre-emptively modifying clinical management based on positive MRD results can improve outcomes, the post-transplant use of donor lymphocyte infusions and/or hypomethylating agents, informed by positive molecular MRD determinations, may be of clinical benefit [16, 59] . The translation of this prognostic information into practical therapeutic action is the next obvious target for intense investigation, including prospective MRD-triggered clinical trials.
Mutations affecting epigenetic modifiers (TET2, DNMT3A, or ASXL1) that are often pre-leukemic mutations associated with clonal hematopoiesis of undetermined potential (CHIP) [60] [61] [62] can be stable and often persist after AML induction chemotherapy. The prognostic relevance of these post-treatment persisting pre-leukemic mutations has been a controversial question, with some studies suggesting that persisting pre-leukemic mutations (particularly in the DNMT3A gene) impart no (or minimally) significant prognostic utility [48, 63, 64] , while other studies have shown that the post-treatment persistence of any leukemia-associated mutation, including pre-leukemic mutations, is associated with an inferior outcome [50, 54, 58, 65] . A rigorously powered study to quantitatively address whether these persisting pre-leukemic mutations impart a significant risk for poor outcomes and are thus suitable MRD biomarkers would require large cohort studies.
Myeloid Neoplasms with Germline Predisposition
The current WHO classification system introduced "myeloid neoplasms with germline predisposition" as a new class of myeloid neoplasms [4] , which is echoed by the 2017 ELN guidelines [3] and the NCCN guidelines [16] . Like many other familial cancer syndromes, these inherited myeloid tumors share a similar profile of pathogenic gene mutations as their somatically acquired counterparts, and the differentiation between these inherited and acquired leukemias at the clinical and histopathological level is usually not possible [4] . Some of these patients may present with a telltale family history suggestive of an inherited cancer predisposition syndrome, while others are identified only after definitive molecular diagnostic characterization of the proband (with or without the family) [66] .
Among the patients diagnosed with an AML with biallelic CEBPA mutation, for example, ~ 10% were reported to carry a germline CEBPA mutation [67, 68] , which is likely providing the first (inherited) genetic 'hit' in a Knudson two-hit hypothesis tumorigenic process. Similarly, GATA2 mutations in pediatric AML/MDS patients will also be germline-derived in ~ 10% of cases [69] . The recognition and diagnosis of myeloid malignancies that may arise from a predisposing germline mutation are critical for optimal clinical management of the patient and his/her family, especially for patients who are considering sibling donor allogeneic HSC transplantation (HSCT). Multiple reports have documented poor post-transplant AML outcomes-including poor engraftment, graft failure, and donor-derived leukemia-after transplantation with sibling-derived stem cells containing the familial AML-predisposing mutation [70] [71] [72] [73] . To avoid these preventable poor outcomes, potential sibling HSCT donors could be screened for multiple prevalent inherited cancer predisposition mutations [66] , or the unique putative family-specific mutation(s). Before implementing such donor screening procedures, however, additional studies will be necessary to assess the potential risks and benefits, including inappropriately rejecting sibling donors with pathogenically unproven genetic variants. Identifying the familial mutation, however, can also inform the decision on the choice of transplant preparative regimens for the AML proband. Cytotoxic HSCT regimens may, for example, significantly increase the risk of solid tumors in Fanconi anemia (FA) patients [74] , and patients with telomere biological disorders may be exquisitely sensitive to harsh myeloablation regimens and require a reduced-intensity treatment [75] [76] [77] . Furthermore, patients or their family members with germline RUNX1, ANKRD26, or ETV6 mutations can experience bleeding episodes out of proportion to their platelet counts, and may require prophylactic platelet transfusion prior to invasive procedures [4] . Although inherited hematological malignancy syndromes have historically been considered to be rare, recent studies have demonstrated that germline cancer predisposition mutations as a whole may not be uncommon, existing in 11-37% of families with hereditary MDS/AML [78] [79] [80] . Even among elderly patients with AML without a family history, the prevalence of pathogenic germline cancer predisposition mutations was an unexpectedly high 14% in the recent Beat AML master trial [103] . A panel of gene mutations associated with increased risk for myeloid malignancies (CEBPA, DDX41, RUNX1, ANKRD26, ETV6, GATA2, SRP72, TP53, ATG2B/GSKIP, TERC, TERT, NF1, PTPN11, etc.) has been suggested to be incorporated into routine molecular diagnostic evaluations of AML patients [81] . Many of these genes are especially relevant to detect in adult AML patients because (1) some mutations predispose to adult-or late-onset (vs. pediatric) disease (e.g., DDX41, TERC, TERT); (2) some mutations have no associated prodrome or constitutional malformation phenotype to raise the suspicion for a germline predisposition (e.g., DDX41, CEBPA); and (3) there is often no discernable family history for recognition of certain inherited syndromes due to incomplete penetrance or variable expressivity (e.g., GATA2, FA genes). Uncovering these underlying germline pathogenic mutations through NGS-based molecular analyses can improve our ability to not only identify these patients, but also to counsel them and their family members for disease risk, cancer surveillance, and possible mutation-informed therapeutic interventions.
Patients with potential germline gene alterations may be detected on NGS panels intended for the detection of somatic mutations in myeloid neoplasms. NGS testing of non-hematopoietic constitutional or post-treatment (hematopoietic) remission samples should be considered for the confirmation of germline pathogenic mutations associated with hematological malignancies. Data have shown that saliva, buccal swab, or direct skin samples collected at the time of diagnosis of a hematopoietic malignancy will be variably contaminated with leukemic cells, thus confounding the interpretation of germline status [82, 103] . Cultured skin fibroblasts are the current gold standard for tumor-normal paired genotyping, with the caveat of being labor intensive and not routinely performed in many clinical diagnostic laboratories.
Conclusion
AML is a genetically heterogeneous malignancy that is difficult to cure. NGS-based assays targeting a panel of consensus gene mutations associated with AML leukemogenesis have become increasingly available in clinical diagnostic laboratories over the last few years. Enhanced NGS-based assays and bioinformatics tools that capture not only the short DNA sequence mutations but also copy number variants, as well as AML-related chromosome translocations via RNA sequencing, are emerging, providing time-sensitive and cost-effective comprehensive mutation profiling for AML patients [83] . Critical, clinically useful information provided by this molecular testing can directly inform the disease diagnosis, choice of therapy, risk stratification, and MRD-based disease monitoring for AML patients, and can improve the long-term outcome for patients with this common deadly leukemia.
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